CAS 85278-24-6 MDL-72274 HCl

MDL-72274 HCl - CAS 85278-24-6

Catalog number: 85278-24-6

Not Intended for Therapeutic Use. For research use only.

Molecular Formula:
Molecular Formula	C9H11Cl2N
Molecular Weight:
Molecular Weight	204.09
COA:
COA	Inquire
Targets:
Targets	Others
Description:
Description	MDL-72274 is a selective SSAO inhibitor. It is a potent (IC50 = 10(-9) M) inhibitor of both MAO-B and SSAO, with 190-fold lower affinity for MAO-A. MDL-72974 can be used for the treatment of Parkinson diseases.

Publication citing BOC Sciences Products

1. An advanced TALSPEAK concept for separating minor actinides. Part 2. Flowsheet test with actinide-spiked simulant

2. YAP-mediated mechanotransduction determines the podocyte's response to damage

3. Analyses of Calcium-Independent Phospholipase A2beta (iPLA2β) in Biological Systems

4. Antiviral activity of Favipiravir (T-705) against a broad range of paramyxoviruses in vitro and against Human Metapneumovirus in hamsters

5. Lipoxin A4 preconditioning attenuates intestinal ischemia reperfusion injury through Keap1/Nrf2 pathway in a lipoxin a4 receptor independent manner

6. Identification of volatiles from Pinus silvestris attractive for Monochamus galloprovincialis using a SPME-GC/MS platform

>> More

Purity:
Purity	98%
Appearance:
Appearance	Powder
Synonyms:
Synonyms	(E)-3-chloro-2-phenylprop-2-en-1-amine hydrochloride
Solubility:
Solubility	Soluble in DMSO
Storage:
Storage	-20℃ Freezer
MSDS:
MSDS	Inquire
Application:
Application	Parkinson diseases
Quality Standard:
Quality Standard	In-house standard
Shelf Life:
Shelf Life	2 month in rt, long time

Quantity:
Quantity	Milligrams-Grams
Canonical SMILES:
Canonical SMILES	NC/C(C1=CC=CC=C1)=C/Cl.[H]Cl

1.Haloallylamine inhibitors of MAO and SSAO and their therapeutic potential.

Palfreyman MG;McDonald IA;Bey P;Danzin C;Zreika M;Cremer G J Neural Transm Suppl. 1994;41:407-14.

Based on mechanistic understandings, molecular modeling and extensive quantitative structure-activity relationships, appropriately substituted haloallylamine derivatives were designed as potential mechanism-based inhibitors of MAO and/or SSAO. Potent inhibition of MAO-B and SSAO occurred with fluoroallylamines whereas chloroallylamines, such as MDL 72274A ((E)-2-phenyl-3-chloroallylamine hydrochloride), were selective and potent inhibitors of SSAO. MDL 72974A (E)-2-(4-fluorophenethyl)-3-fluoroallylamine hydrochloride is a potent (IC50 = 10(-9) M) inhibitor of both MAO-B and SSAO, with 190-fold lower affinity for MAO-A. In clinical studies, oral doses as low as 100 micrograms produced substantial inhibition of platelet MAO-B. Essentially complete inhibition occurred at 1 mg with the effect lasting 6-10 days. One or 4 mg MDL 72974A given daily for 28 days to 40 Parkinson's patients treated with L-dopa produced statistically significant reductions in the Unified Parkinson's Disease Rating Scale. MAO-B inhibitors, such as MDL 72974A and L-deprenyl, offer the potential of being neuroprotective in Parkinson's Disease and other neurogenerative disorders. Concommitant inhibition of SSAO may provide additional, but as yet unproven, advantages over pure inhibitors of MAO-B.

Molecular Weight Calculator Molarity Calculator Solution Dilution Calculator

Related Products

Quick Inquiry

Featured Items

Drug Discovery

Chemistry

Life Science